Bone Morphogenetic Protein Pathway Linked to Parkinson's Disease Risk and Motor Recovery in Study
Researchers have identified the bone morphogenetic protein (BMP) signaling pathway as a contributor to Parkinson's disease genetic risk and demonstrated that BMP5 and BMP7 proteins can protect and restore dopaminergic neurons in mouse models. A BMP polygenic risk score was significantly associated with increased PD risk (OR = 1.21), and the finding was replicated in a proxy-case analysis. The results suggest BMP pathway modulation could represent a novel disease-modifying therapeutic strategy for Parkinson's disease.
A new preprint study on bioRxiv reports that variations in the bone morphogenetic protein (BMP) signaling pathway contribute to polygenic Parkinson's disease (PD) risk, based on analyses of common and rare genetic variants across large-scale datasets. A BMP polygenic risk score (PRS) showed a significant association with PD risk (OR = 1.21, empirical P = 1.0×10⁻⁴), a result replicated in proxy-case analyses (OR = 1.14) and confirmed through sensitivity testing. To validate functional relevance, the researchers genetically and pharmacologically inhibited BMP signaling in mice, which produced motor deficits and PD-like neuropathology, mirroring human disease features. In an alpha-synuclein preformed fibril (PFF) mouse model — a standard preclinical PD system — administration of BMP5 and BMP7 concurrently with PFFs provided neuroprotective effects. Critically, when BMP5/7 was delivered after motor symptom onset, it demonstrated neurorestorative properties, reducing both motor impairments and neuropathology. The authors describe these as the first findings linking BMP signaling variation to polygenic PD risk and propose the pathway as a candidate target for disease-modifying therapies.
What's missing
As a preprint, this study has not yet undergone peer review, and its findings should be interpreted with caution. The study's own limitations likely include the translational gap between mouse models and human Parkinson's disease, the use of PFF models which recapitulate only certain aspects of PD pathology, and uncertainty about whether BMP5/7 administration would be safe and feasible in human patients. Long-term outcomes and optimal dosing or delivery mechanisms for BMP5/7 in a therapeutic context remain unaddressed.
What different sources said
- bioRxivCenter
Bone Morphogenetic Protein Pathway Modulates Parkinson's Disease Genetic Risk and Promotes Motor Recovery
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.